Orum Therapeutics to Present Preclinical Data for ORM-5029, a Novel Antibody Neodegrader Conjugate, at the AACR Annual Meeting 2022
BOSTON & DAEJEON, South Korea–(BUSINESS WIRE)–#AACR22–Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders, today announced that the Company will present preclinical data for ORM-5029 at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 taking place April 8-13 virtually and in-person at the Ernest N. Morial Convention Center in New Orleans. Orum is developing ORM-5029 as a potential first-in-class targeted protein degrader therapy for HER2-expressing breast cancer.
Presentation Details
Poster Title: ORM-5029: A first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer
Date and Time: Wednesday, April 13, 9:00 AM – 12:30 PM EDT
Virtual E-Poster Viewing: April 8 to July 13
Session Category: Experimental and Molecular Therapeutics
Session Title: Emerging New Anticancer Agents
Session Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 22
Poster Board Number: 7
Abstract number: 3933
About Orum�s AnDC Platform
Orums Antibody neoDegrader Conjugate (AnDC) platform is built on novel targeted protein degrader (TPD) combined with the precise tumor cell delivery mechanisms of antibodies to generate innovative, first-in-class cell-specific TPD for the treatment of cancer. The company has developed new molecular glue degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, neoDegraders are designed to be delivered specifically to cancer cells and degrade the intracellular target protein and cause tumor cell death.
About Orum Therapeutics
Orum Therapeutics is pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD2 approach to provide dual precision, antibody-enabled targeted protein degraders for cell-specific delivery. The Companys proprietary platforms generated using the TPD2 approach includes the Antibody neoDegrader Conjugate (AnDC) platform, which generates first-in-class antibody drug conjugates. The first therapeutic candidates from the AnDC platform are in development for the treatment of solid tumors and hematologic cancers. Orum is located in Cambridge, Massachusetts, and Daejeon, South Korea. For more information, visit www.orumrx.com.
Contacts
Corporate: Kyuri Kim Ph.D., Business Development Associate, Orum Therapeutics, contact@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., +1-858-344-8091, jessica@litldog.com
Recent Posts
“One Earth Summit” 2025 Held Successfully Hong Kong Fully Leverages Its Role as an International Financial Center and Leader in Green Finance
Laying a Solid Foundation for the Development of ESG Investment and Green Innovation Calling for…
The Campaign “It’s Time for EU Beef” is coming to Cebu and Manila in April
The Philippine meat industry will be shown the quality and guarantees of European beef MANILA,…
European beef will continue to play aleading role in Singapore in the coming months of 2025
"It’s Time for European Beef" is a campaign led by Provacuno and co-funded by the…
Make Waves at Galaxy Macau: Dive into a Luxurious One-Stop Ultimate Holiday Escape with the Reopening of the Grand Resort Deck
MACAU SAR - Media OutReach Newswire - 27 March 2025 - The world-class luxurious Galaxy…
Diabetes Association Unveils T-CaReMe Taipei Declaration at the Asia Diabetes International Conference
In an effort to achieve a target of 80% of patients controlling the three highs…
Li Ning Company Limited Announces 2024 Annual Results
Strengthen the “Single Brand, Multi-Categories, Diversified Channels” Strategy | Solidify Brand and Product Competitiveness, Ensure…